1. Home
  2. VIVS vs AIXI Comparison

VIVS vs AIXI Comparison

Compare VIVS & AIXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VivoSim Labs Inc. Common Stock

VIVS

VivoSim Labs Inc. Common Stock

HOLD

Current Price

$2.40

Market Cap

8.1M

Sector

Health Care

ML Signal

HOLD

AIXI

XIAO-I Corporation

HOLD

Current Price

$0.65

Market Cap

8.9M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
VIVS
AIXI
Founded
2007
2001
Country
United States
China
Employees
N/A
162
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
8.1M
8.9M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
VIVS
AIXI
Price
$2.40
$0.65
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
46.0K
199.4K
Earning Date
11-06-2025
12-26-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$140,000.00
$70,314,315.00
Revenue This Year
$42.38
$26.84
Revenue Next Year
$15.42
N/A
P/E Ratio
N/A
N/A
Revenue Growth
35.92
18.84
52 Week Low
$1.41
$0.60
52 Week High
$21.96
$6.65

Technical Indicators

Market Signals
Indicator
VIVS
AIXI
Relative Strength Index (RSI) 49.83 36.38
Support Level $2.11 $0.64
Resistance Level $2.40 $0.71
Average True Range (ATR) 0.13 0.08
MACD 0.03 0.01
Stochastic Oscillator 54.92 17.26

Price Performance

Historical Comparison
VIVS
AIXI

About VIVS VivoSim Labs Inc. Common Stock

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

About AIXI XIAO-I Corporation

XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.

Share on Social Networks: